Pierre M Sié

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7205364/publications.pdf

Version: 2024-02-01

206121 182225 2,633 64 30 51 citations h-index g-index papers 69 69 69 3797 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Platelet activation and partial desensitization are associated with viral xenophagy in patients with severe COVID-19. Blood Advances, 2022, 6, 3884-3898.	2.5	12
2	Role of oculocerebrorenal syndrome of Lowe (OCRL) protein in megakaryocyte maturation, platelet production and functions: a study in patients with Lowe syndrome. British Journal of Haematology, 2021, 192, 909-921.	1.2	6
3	Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination. Thrombosis Research, 2021, 203, 163-171.	0.8	52
4	Oxford-AstraZeneca COVID-19 vaccine-induced cerebral venous thrombosis and thrombocytopaenia: A missed opportunity for a rapid return of experience. Anaesthesia, Critical Care & Description (2021, 40, 100889).	0.6	11
5	Effects of novel Btk and Syk inhibitors on platelet functions alone and in combination in vitro and in vivo. Journal of Thrombosis and Haemostasis, 2020, 18, 3336-3351.	1.9	8
6	Thromboembolic events and Covid-19. Advances in Biological Regulation, 2020, 77, 100735.	1.4	61
7	Strengths and Weaknesses of Light Transmission Aggregometry in Diagnosing Hereditary Platelet Function Disorders. Journal of Clinical Medicine, 2020, 9, 763.	1.0	20
8	Platelet Activation Is Limited during Transcatheter Aortic Valve Implantation in Patients on Aspirin Monotherapy and without per Procedural Clinical Complications. TH Open, 2019, 03, e146-e152.	0.7	0
9	Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions. Haematologica, 2019, 104, 2292-2299.	1.7	39
10	Management of bleeding and emergency invasive procedures in patients on dabigatran: Updated guidelines from the French Working Group on Perioperative Haemostasis (GIHP) –ÂSeptember 2016. Anaesthesia, Critical Care & Pain Medicine, 2018, 37, 391-399.	0.6	36
11	Platelet activation and prothrombotic properties in a mouse model of peritoneal sepsis. Scientific Reports, 2018, 8, 13536.	1.6	44
12	Management of Severe Bleeding in Patients Treated with Direct Oral Anticoagulants. Anesthesiology, 2017, 127, 111-120.	1.3	52
13	Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study. Thrombosis Research, 2017, 158, 126-133.	0.8	26
14	Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP)Ââ \in "ÂSeptember 2015. Anaesthesia, Critical Care & Pain Medicine, 2017, 36, 73-76.	0.6	66
15	Î-storage pool disease: an underestimated cause of unexplained bleeding. Hematologie, 2017, 23, 243-254.	0.0	4
16	Management of invasive procedures in patients with platelet disorders or thrombocytopenia Guidelines by French expert group on inherited platelet diseases. Sang Thrombose Vaisseaux, 2017, 29, 149-156.	0.1	1
17	Strengths and weaknesses of platelet aggregation in diagnosis of hereditary platelet disorders. Hematologie, 2017, 23, 298-311.	0.0	1
18	Alterations of the Platelet Procoagulant or Fibrinolytic Functions., 2017,, 937-949.		0

#	Article	IF	CITATIONS
19	The class I phosphoinositide 3-kinases $\hat{l}\pm$ and \hat{l}^2 control antiphospholipid antibodies-induced platelet activation. Thrombosis and Haemostasis, 2016, 115, 1138-1146.	1.8	13
20	Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran. Drug Design, Development and Therapy, 2016, 10, 1683.	2.0	9
21	A diagnostic approach that may help to discriminate inherited thrombocytopenia from chronic immune thrombocytopenia in adult patients. Platelets, 2016, 27, 555-562.	1.1	18
22	Expanding the Mutation Spectrum Affecting αIIbβ3 Integrin in Glanzmann Thrombasthenia: Screening of the <i>ITGA2B</i> and <i>ITGB3</i> Genes in a Large International Cohort. Human Mutation, 2015, 36, 548-561.	1.1	67
23	Platelet Adhesion and Thrombus Formation in Whole Blood at Arterial Shear Rate at the End of Pregnancy. American Journal of Reproductive Immunology, 2015, 74, 533-541.	1.2	9
24	Platelet activation and arterial peripheral serotonin turnover in cardiac remodeling associated to aortic stenosis. American Journal of Hematology, 2015, 90, 15-19.	2.0	26
25	Management of bleedings and prevention recommendations in patients taking ibrutinib for lymphoma therapy. Hematologie, 2015, 21, 230-233.	0.0	1
26	Pathophysiology of inherited platelet disorders. Hematologie, 2014, 20, 20-35.	0.0	3
27	Pathophysiology of inherited platelet disorders. Sang Thrombose Vaisseaux, 2014, 26, 300-316.	0.1	0
28	Gestion périopératoire des nouveaux anticoagulants. Praticien En Anesthesie Reanimation, 2014, 18, 52-59.	0.0	0
29	Gestion p $ ilde{A}$ ©ri-op $ ilde{A}$ ©ratoire des nouveaux anticoagulants oraux. Journal Europeen Des Urgences Et De Reanimation, 2014, 26, 173-180.	0.1	0
30	Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood, 2014, 124, 3991-3995.	0.6	265
31	Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia. Haematologica, 2014, 99, 1387-1394.	1.7	63
32	Inherited platelet disorders and oral health. Journal of Oral Pathology and Medicine, 2013, 42, 115-124.	1.4	15
33	Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis (GIHP) – March 2013. Archives of Cardiovascular Diseases. 2013. 106. 382-393.	0.7	281
34	Chronic estradiol treatment reduces platelet responses and protects mice from thromboembolism through the hematopoietic estrogen receptor \hat{l}_{\pm} . Blood, 2012, 120, 1703-1712.	0.6	54
35	Surgery and invasive procedures in patients on long term treatment with oral direct thrombin or factor Xa inhibitors (update 2012). Sang Thrombose Vaisseaux, 2012, 24, 269-278.	0.1	2
36	Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: Thrombin or factor-Xa inhibitors. Recommendations of the Working Group on perioperative haemostasis and the French Study Group on thrombosis and haemostasis. Archives of Cardiovascular Diseases, 2011, 104, 669-676.	0.7	164

#	Article	IF	Citations
37	Are P2Y12 reaction unit (PRU) and % inhibition index equivalent for the expression of P2Y12 inhibition by the VerifyNow® assay? Role of haematocrit and haemoglobin levels. Thrombosis and Haemostasis, 2011, 106, 227-229.	1.8	27
38	Short-term effects of the smoke-free legislation on haemostasis and systemic inflammation due to second hand smoke exposure. Thrombosis and Haemostasis, 2011, 105, 1024-1031.	1.8	4
39	Nouvelles molécules ciblées etÂmodulation desÂfonctions plaquettaires: anticiper, démontrer, gérer, utiliser. Hematologie, 2010, 16, 345-354.	0.0	0
40	Renal biopsy practice in France: results of a nationwide study. Nephrology Dialysis Transplantation, 2010, 25, 3579-3585.	0.4	30
41	French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding). Thrombosis Research, 2010, 126, e167-e174.	0.8	127
42	Association of neutrophil count with microembolization in patients with symptomatic carotid artery stenosis. Atherosclerosis, 2009, 207, 519-523.	0.4	33
43	The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood, 2009, 114, 1884-1892.	0.6	110
44	Microparticles from apoptotic monocytes induce transient platelet recruitment and tissue factor expression by cultured human vascular endothelial cells via a redox-sensitive mechanism. Thrombosis and Haemostasis, 2007, 98, 831-837.	1.8	64
45	Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. Thrombosis and Haemostasis, 2007, 97, 949-954.	1.8	92
46	Comparison of three activated protein C resistance tests in the risk assessment of venous thrombosis in non-carriers of the factor V Leiden mutation. Thrombosis and Haemostasis, 2006, 95, 728-734.	1.8	3
47	Microparticles from apoptotic vascular smooth muscle cells induce endothelial dysfunction, a phenomenon prevented by \hat{l}^23 -integrin antagonists. Thrombosis and Haemostasis, 2005, 94, 853-8.	1.8	40
48	Integrin-dependent interaction of lipid rafts with the actin cytoskeleton in activated human platelets. Journal of Cell Science, 2005, 118, 759-769.	1.2	70
49	Reassessment of von Willebrand factor (VWF), VWF propeptide, factor VIII:C and plasminogen activator inhibitors 1 and 2 during normal pregnancy. British Journal of Haematology, 2003, 121, 897-903.	1.2	33
50	Utilisation and Safety of Low Molecular Weight Heparins. Drug Safety, 2003, 26, 197-207.	1.4	59
51	Standardization of factor VII/activated factor VII measurement in plasma of patients treated with recombinant factor activated VII. Blood Coagulation and Fibrinolysis, 2003, 14, 505-511.	0.5	13
52	The Expression of Tissue Factor and Tissue Factor Pathway Inhibitor in Aortic Smooth Muscle Cells Is Up-regulated in Synthetic Compared to Contractile Phenotype. Thrombosis and Haemostasis, 2002, 87, 1051-1056.	1.8	10
53	The Effect of Platelet PIA Polymorphism on Experimental Thrombus Formation in Man Depends on Blood Flow and Thrombogenic Substrate. Thrombosis and Haemostasis, 2001, 85, 1097-1103.	1.8	7
54	Role of 4 platelet membrane glycoprotein polymorphisms on experimental arterial thrombus formation in men. Blood, 2001, 98, 3159-3161.	0.6	40

#	Article	IF	CITATIONS
55	Molecular bases of antithrombin deficiency in French families: identification of seven novel mutations in the antithrombin gene. British Journal of Haematology, 2000, 110, 731-734.	1.2	16
56	Effects of Lysophosphatidic Acid on Proliferation and Cytosolic Ca++ of Human Adult Vascular Smooth Muscle Cells in Culture. Thrombosis Research, 1999, 94, 317-326.	0.8	41
57	Acute basophilic leukaemia and translocation $t(X;6)(p11;q23)$. British Journal of Haematology, 1997, 98, 170-176.	1.2	39
58	Different glycoforms of human thrombomodulin. Their glycosaminoglycan-dependent modulatory effects on thrombin inactivation by heparin cofactor II and antithrombin III. FEBS Journal, 1991, 198, 563-570.	0.2	44
59	3 Pharmacokinetics of heparin and low molecular weight heparin. Best Practice and Research: Clinical Haematology, 1990, 3, 531-544.	1.1	81
60	Leishmania donovani: Cell-surface heparin receptors of promastigotes are recruited from an internal pool after trypsinization. Experimental Parasitology, 1990, 71, 49-59.	0.5	18
61	Studies on the structural requirements of heparin for the catalysis of thrombin inhibition by heparin cofactor II. Biochimica Et Biophysica Acta - General Subjects, 1988, 966, 188-195.	1.1	36
62	Pharmacokinetic Studies of Standard Unfractionated Heparin, and Low Molecular Weight Heparins in the Rabbit. Seminars in Thrombosis and Hemostasis, 1988, 14, 18-27.	1.5	103
63	Changes in Plasma Fibronectin Levels After Cardiac and Pulmonary Surgery: Role of Cardiopulmonary Bypass. Scandinavian Journal of Thoracic and Cardiovascular Surgery, 1985, 19, 63-67.	0.2	11
64	Exhausted platelets in patients with malignant solid tumors without evidence of active consumption coagulopathy. European Journal of Cancer & Clinical Oncology, 1984, 20, 899-903.	0.9	34